Synergy Pharmaceuticals Incorporated (SGYP)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.01 / 0.04
Exchange NASDAQ
Div & Yield N.A. (N.A)

Synergy Pharmaceuticals To Present At The Jefferies 2017 Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present a corporate update at the Jefferies Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 2:00 p.

Short Interest Moves 20.6% Lower For SGYP

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 14,132,134 share decrease in total short interest for Synergy Pharmaceuticals Inc , to 54,425,438, a decrease of 20.61% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Synergy Pharmaceuticals To Present Positive TRULANCE™ (Plecanatide) Phase 3 Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present late-breaking data from Phase 3 studies evaluating TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel...

Synergy Presents New Insights At Digestive Disease Week (DDW) Examining Patient And Physician Perceptions And Experiences With Chronic Idiopathic Constipation (CIC)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with managing their condition.

Synergy Pharmaceuticals To Present TRULANCE™ (Plecanatide) Phase 3 Data At Digestive Disease Week (DDW) For The Treatment Of Adults With Chronic Idiopathic Constipation (CIC) With Moderate To Very Severe Bloating

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company will present new data from an analysis of patients with moderate to very severe bloating at baseline who participated in two Phase 3 studies...

Synergy Pharmaceuticals To Highlight New Data For TRULANCE™ (Plecanatide) At Digestive Disease Week (DDW)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present six abstracts, including a late-breaker oral presentation showing new data on TRULANCE for the treatment of adults with irritable...

Synergy Pharmaceuticals To Present At The 42nd Annual Deutsche Bank Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present a corporate update at the 42 nd Annual Deutsche Bank Healthcare Conference in Boston on Wednesday, May 3, 2017 at 12:50 p.

Relative Strength Alert For Synergy Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Gary G. Gemignani, EVP And CFO, Synergy Pharmaceuticals Inc. (Photo: Business Wire)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary G.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Synergy Pharmaceuticals Announces Issuance Of Three New Patents Expected To Extend TRULANCE™ (Plecanatide) Patent Protection Until 2032

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents covering TRULANCE (plecanatide).

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Plugged-Up Paulie (Animated) (Photo: Business Wire)

Synergy Pharmaceuticals today announced the launch of the Poop Troop, a series of 14 animated emojis designed to encourage conversation and allow people to better express the physical and emotional impact of chronic...

Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) For TRULANCE™ (Plecanatide) For The Treatment Of Adults With Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company has submitted a supplemental New Drug Application (sNDA) for TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel...

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Synergy Pharmaceuticals To Present At Oppenheimer 27th Annual Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Oppenheimer 27 th Annual Healthcare Conference on...

CORRECTING and REPLACING Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update

Please replace the release, dated March 1, 2017, with the following corrected version due to multiple revisions in the Financial Results bullets and financial tables.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Synergy Pharmaceuticals To Present At Leerink Partners 6th Annual Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Marino Garcia, the company's EVP and Chief Strategy Officer, will participate in a fireside chat at Leerink Partners 6 th Annual Global Healthcare Conference...

Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the efficacy and safety of...

Synergy, Portola Still in My Sights

Synergy, Portola Still in My Sights

Both pharma companies are promising names that easily could become buyout targets.

How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices

How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices

Here's how to trade seven of the most active stocks on the market on Wednesday afternoon.

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Synergy Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the pricing of its underwritten public...

Synergy Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced an agreement to sell $125 million of...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.